. Sequencing chromatograms confirm presence of the signature BRCA1 mutations and lack of corresponding wild-type alleles in four BRCA1-mutant cell lines. Figure S2 . PARP cleavage in BRCA1-mutant cell lines upon drug treatment. Table T1 . Results of the high-throughput screen shown as differential drug sensitivity scores (dDSS).
Supplementary
. Sequencing chromatograms confirm presence of the signature BRCA1 mutations and lack of corresponding wild-type alleles in four BRCA1-mutant cell lines. Picks corresponding to mutant nucleotides are marked with arrows. Wild-type BRCA1 sequence encompassing the region of interest is shown at the top of each image and mutant codons are marked with black boxes. Figure S2 . PARP cleavage in BRCA1-mutant cell lines upon drug treatment. Cells were treated with drugs at indicated concentrations for 18 hours and lysed for Western blotting. Amount of cleaved poly (ADP-ribose) polymerase (cPARP) reflects ongoing apoptosis. GAPDH serves as loading control. * -DSS were calculated for each drug and normalized by the logarithm of the top response. Positive dDSS values indicate sensitivity relative to the average from all cell lines, negative -relative resistance, respectively. "Delta" column shows the difference between average dDSS score for all BRCA1-mutant cell lines and the average for all BRCA1-wildtype cells (positive Delta indicates that BRCA1-mutant cells are mostly resistant relative to control cell lines). Results for MEK1/2 inhibitors are highlighted in red.

